Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:25:43.615Z.
Calculation as of: 2026-10-06T16:25:43.615Z.
Quote observation: 2026-10-06T16:24:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d88ebff11657cb0645ea93f74423bc241bf41286751ec96f31399ab1bd3406dc
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $8.05M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.11M | N/A | N/A | N/A | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.34M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.96M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.86M | N/A | 0.17 | 0.28 | 0.28 |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.53M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.71M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.29M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.36M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.65
Forward EPS (Est.)
$-0.29
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
